Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter? in the upadacitinib ph3 trials, high disease activity pts had more: serious infections HZ MACE VTE Active RA is a massive contributor to many AEs in JAKi pts #ACR24 ABST1393 @RheumNow https://t.co/DlFf9Sfbja

• https://x.com/drdavidliew/status/1858190305398497317/photo/1

Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy

• Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab vers…
• https://x.com/RichardPAConway/status/1858190864708780251/photo/1

Harkins @DrTrishHarkins et al. PROs predict relapse in PMR. pVAS, HAQ health status, FACIT-F all positive predictors. Interestingly PHQ-9 negative predictor. @RheumNow #ACR24 Abstr#1238 https://t.co/kj4WgmI0oq https://t.co/xLDzRZvxoA

• Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in …
• https://x.com/RichardPAConway/status/1858191116337590456/photo/1

Gottlieb et al. TYK2i Zasocitinib in PsA. 12 week phase 2 RCT. Skin responses and MDA all favour zasocitinib but maybe not fantastic? PASI75 46%, PASI90 37%, PASI100 26%. MDA in photo. @RheumNow #ACR24 Abstr#1477 https://t.co/iX5iriESV2 https://t.co/RkEmcAZ80x

• Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibit…
• https://x.com/RichardPAConway/status/1858192626425749820/photo/1

Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/YvQnmmvNjF https://t.co/crYUwHahDb

• Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Di…
• https://x.com/RichardPAConway/status/1858183818525753664/photo/1

The idea of patient-initiated follow-up for RA is enticing: patient & physician time is already stretched minimize unnecessary visits/improve access but what actually needs to go into the design, to make it safe/workable? A: plenty. 🇨🇦 pilot underway #ACR24 ABST1041 @RheumNow https://t.co/03u4bhnQ0v

• https://x.com/drdavidliew/status/1858184151306047682/photo/1

STAR trial of GC w/d in RA LDA SEMIRA of GC w/d controlled RA on Toci Very slight disease activity increase, but higher flares No symptomatic adrenal insufficiency, but data of abnormal ACTH stim No good evidence of steroid w/d symptoms Beth Wallace @RheumNow #ACR24 https://t.co/j6UPWlVNIu

• https://x.com/ericdeinmd/status/1858185033858593232/photo/1
• https://x.com/ericdeinmd/status/1858185033858593232/photo/1
• https://x.com/ericdeinmd/status/1858185033858593232/photo/1

Slick poster, but must be careful w/real world data. Big risk of confounding/channeling bias Pts with MACE risk (not always well-characterized by ICD codes) also less likely to receive JAK & therefore less liekly to have subsequent MACE #ACR24 @RheumNow Abstr#1394 https://t.co/lilU0byJ1s

• https://x.com/EBRheum/status/1858185076560830717/photo/1

Zhou et al. Phase 2 RCT of XKH004, IL17A/Fi in AxSpA. ASAS40 50.4% vs 25%. Slightly odd dose response variation, but maybe just noise. @RheumNow #ACR24 Abstr#1453 https://t.co/SsTSThFzro https://t.co/C9yK2G4tqB

• Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal…
• https://x.com/RichardPAConway/status/1858185580116328614/photo/1

Getting more data on using deucravacitinib for PsO/PsA manifestations Impressive effect on scalp psoriasis (which often means a lot to patients) Given how safe it is, it's increasingly tempting to use more of it in mild-mod PsA #ACR24 PSORIATYK SCALP trial ABST1137 @RheumNow https://t.co/vxS3RSlIN0

• https://x.com/drdavidliew/status/1858185727491919901/photo/1

Cowley et al. US pattern in Subclinical GCA in PMR vs GCA. Subclinical GCA has more isolated axillary artery involvement. Severity of US inflammation significantly higher in GCA than subclincal GCA @RheumNow #ACR24 Abstr#1629 https://t.co/6Iyx76YgkS https://t.co/DxzTEwE5J5

• Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica Has a Different Vasc…
• https://x.com/RichardPAConway/status/1858185832555020629/photo/1

Abst #1473 evaluated association of SJC in PROs from 2 Bimekizumab trials (bDMARD naïve vs TNFi-IR) -bDMARD naïve had less SJC at baseline -In both groups, pts w lower SJC had sustained improvement in pain and fatigue over time. #ACR24 @RheumNow https://t.co/zwxsSbga7c

• https://x.com/AdelaCastro222/status/1858180798488424715/photo/1

Findings from Abstr#1436 reveal that cigarette smoking is not positively associated with radiographic progression in psoriatic arthritis (PsA). Current and past smokers showed a longer time to joint damage progression. This suggests a complex relationship that warrants further… https://t.co/ERsAKoivA4

• https://x.com/i/web/status/1858182057098367025

What do current national/international rheumatology association guidelines say about perioperative discontinuation of biologics? it's highly, highly variable no wonder people get confused! #ACR24 ABST1037 @CatherineL_Hill @RheumNow https://t.co/cmJ3qKU1QT

• https://x.com/drdavidliew/status/1858182160169242882/photo/1

Serrano-Combarro et al. Case series of upadacitinib in RA-ILD. 18 patients. Report stable/improved dyspnoea and HRCT over 12 months. PFTs shown, relatively stable @RheumNow #ACR24 Abstr#1372 https://t.co/yncy0lPq60 https://t.co/mrDMtEDwUt

• Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis …
• https://x.com/RichardPAConway/status/1858182560305532954/photo/1